Valuation dashboard for Septerna Inc (SEPN) with P/E N/A, P/B 5.58, EV/EBITDA -50.3 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 99.6%, operating margin -44.0%, net margin -24.5%.
At $47.88 (closing price, November 4, 2026), SEPN has negative trailing earnings (P/E not meaningful) and an ROE of -6.31%. Market capitalisation stands at $2.2B.
Balance sheet quality for SEPN: debt-to-equity ratio of 0.06, current ratio of 4.99 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.58 |
| EV / EBITDA | -50.3 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SEPN | Septerna Inc | $2.2B | 5.58 | -6.3% | |
| MBX | MBX Biosciences, Inc. Common Stock | $2.5B | 6.11 | -26.0% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $139.2B | 35.33 | 6.66 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $103.2B | 14.63 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.8B | 20.56 | 2.79 | 15.1% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $58.6B | 43.93 | 6.97 | 16.9% |
Price
| Price | $47.88 (closing price, November 4, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -8.89% |
| Return on Assets | -4.28% |
| Gross Margin | 99.57% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
Related companies: MBX · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks